31 July 2024

Graft Polymer (UK) plc

("Graft Polymer" or the "Company")

Total Voting Rights

Graft Polymer (UK) plc (LON:GPL), announces that the Company's issued share capital as at the date of this announcement comprises 2,295,930,633 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 2,295,930,633.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

Enquiries:

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director
Email: yifat@graftpolymer.co.uk

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

+44 (0) 20 3328 5656

About Graft Polymer (UK) Plc

Graft Polymer plc ("Graft Polymer") (LSE:GPL) is an innovative biopolymer drug delivery systems development company dedicated to enabling biopharmaceutical companies to enhance the effectiveness of their therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the pharmacokinetics, bioavailability, and stability of their therapeutics.

For more information, please visit www.graftpolymer.co.uk.